Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jessica Merrill
The small biotech presented positive interim data from a Phase II trial testing its lead candidate SM-88 in prostate cancer at ESMO and is gearing up to initiate a trial in pancreatice cancer.
Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.
Global R&D President Elias Zerhouni said Sanofi has the knowledge and skills it needs to discover antibody drugs internally and it's time to end the perception that Regeneron is keeping Sanofi's R&D humming.
The generic drug maker signed two deals to divest its women's health business, one with the equity investment firm CVC Capital Partners and the other with Foundation Consumer Healthcare.
Pfizer needed good news from the Phase III PROSPER trial testing Xtandi in non-metastatic prostate cancer patients to show investors the Medivation deal was worth the cost. It got what it was hoping for.
Allergan's potential Restasis generic rival wasted no time attacking the company in court documents over the controversial deal Allergan signed with a Native American tribe to thwart generic competition.